Login to Your Account

Corgentech, BMS Enter Graft Deal Valued At Up To $250M

By Randall Osborne

Tuesday, October 14, 2003
With two Phase III trials under way testing its treatment to prevent vein-graft failure after surgery, Corgentech Inc. is joining with Bristol-Myers Squibb Co. in a deal that's expected to get revenue flowing better. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription